Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) is a biopharmaceutical company that discovers, develops, and commercializes pharmaceutical products to treat severe medical conditions. Some of the firm’s products include EYLEA injection and ARCALYST injection. The company’s commercialized medicines are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases, and other rare diseases.
REGN
Regeneron Pharmaceuticals Inc
NASDAQ
966.30
USD
0.29%
+2.75
OPEN
971.04
PREV CLOSE
963.55
DAY RANGE
976.75 - 962.41
VOLUME
314.8K
AVG. VOLUME
463.6K
52 WEEK RANGE
998.33 - 684.81
Buy REGN stocks now with Interactive Brokers – the most advanced investment platform
Valuations metrics
Market capitalization
106.1B
Enterprise value
95.7B
Trailing pe
27.783209
Forward pe
20.44214
Peg ratio
20.44214
Price to sales ttm
8.085797
Price to book mrq
3.9852023
Enterprise to revenue
7.296
Enterprise to ebitda
20.562
Financials
Fiscal year ends
2023-12-31
Most recent quarter
2023-12-31
Profit margin
0.30141002
Operating margin
0.29202
Return on assets ttm
0.08494
Return on equity ttm
0.16258
Income statement
Revenue ttm
13.1B
Revenue per share ttm
122.935
Quarterly revenue growth
0.006
Gross profit ttm
11.3B
Ebitda
5.1B
Net income to common ttm
4B
Diluted eps ttm
34.78
Quarterly earnings growth yoy
-0.031
Balance sheet
Total cash mrq
10.8B
Total cash per share mrq
100.918
Total debt mrq
2.7B
Total debt to equity mrq
10.407
Current ratio mrq
5.69
Book value per share mrq
242.472
Cash flow
Operating cash flow ttm
4.6B
Levered free cash flow ttm
2.8B
Stock statistics
Shares outstanding
107.9M
Float shares
102.8M
Avg 10 volume
463.1K
Avg 90 volume
439.6K
Shares short
1.4M
Short ratio
2.65
Short percent of shares outstanding
0.0147
Percent held by insiders
0.02582
Percent held by institutions
0.89188004
Stock price summary
Fifty two week low
684.81
Fifty two week high
998.33
Fifty two week change
16.02
Beta
0.11
Day 50 ma
957.3264
Day 200 ma
844.101